Camp4 Therapeutics vs Ensysce Biosciences
Ensysce Biosciences is the larger business, with $5.1m of revenue in fiscal 2025 against $3.5m for Camp4 Therapeutics (1.4 times as much). Camp4 Therapeutics grew faster (436.5% against -2.8%). Ensysce Biosciences kept more of each dollar of sales as profit: a net margin of -200.8% against -2298.5%. Camp4 Therapeutics carries less debt relative to equity (0.0% against 9.5%).
| Latest fiscal year | Camp4 TherapeuticsCAMP, 2025 | Ensysce BiosciencesENSC, 2025 |
|---|---|---|
| Revenue | $3.5m | $5.1m |
| Revenue growth | 436.5% | -2.8% |
| Net income | −$80.4m | −$10.2m |
| Operating margin | -1502.4% | -202.1% |
| Net margin | -2298.5% | -200.8% |
| Return on equity | -145.1% | — |
| Free cash flow | −$29.8m | −$7.9m |
| Cash | $110m | $4.3m |
| Total debt | $0 | $306,708 |
| Debt to equity | 0.0% | 9.5% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 48 | — |
| Market value | $201m | $5.9m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 5 buys, 6 sales | 2 buys, 0 sales |